The stock market was doing well on Thursday following Federal Reserve Chair Jerome Powell’s decision to cut interest rates. However, this was short-lived as President Trump sent the markets tumbling after he tweeted that China would face even more tariffs going forward. We saw what happened back in May when the president tweeted something similar, although this time the rate hike might stem the bleeding.
Earnings season has proven to be quite mixed and has created some very big wins or bad misses on individual stock prices. Markets were holding near all-time highs prior to the China tweet, but this serves to give investors another reason to be cautious.
24/7 Wall St. reviews dozens of analyst research reports each day of the week. Our goal is to find new ideas for investors and traders alike. Some of these analyst reports cover stocks to buy, while others cover stocks to sell or to avoid.
Additional commentary has been added on most of the daily analyst reports, along with trading history. The consensus analyst price targets and other valuation metrics are from the Refinitiv (Thomson Reuters) sell-side research service.
These were the top analyst upgrades, downgrades and initiations seen on Friday, August 2, 2019.
Abiomed Inc. (NASDAQ: ABMD) was downgraded to an Equal Weight rating with a $215 price target by Morgan Stanley. Shares closed most recently at $204.87, in a 52-week range of $197.81 to $459.75. The consensus price target is $301.25.
Adaptimmune Therapeutics PLC (NASDAQ: ADAP) was downgraded by Guggenheim to a Neutral rating. Shares closed at $2.95, in a 52-week range of $2.85 to $14.54. The consensus price target is $7.08.
Antero Midstream Corp. (NYSE: AM) was downgraded to a Neutral rating with a $13 price target at Stifel. Shares closed at $8.43, in a 52-week range of $8.20 to $19.61. The consensus price target is $15.46.
BlackLine Inc. (NASDAQ: BL) was maintained with an Overweight rating and a $62 price target at KeyBanc. Shares closed at $42.54, in a 52-week range of $34.01 to $58.11. The consensus price target is $52.33.
Carbon Black Inc. (NASDAQ: CBLK) was maintained with an Overweight rating and a $23 price target at KeyBanc. Shares closed at $18.25, in a 52-week range of $11.80 to $27.27. The consensus price target is $19.60.
Clovis Oncology Inc. (NASDAQ: CLVS) was downgraded to a Neutral rating at Guggenheim. Shares closed at $8.87, in a 52-week range of $8.77 to $41.75. The consensus price target is $27.50.
Fortinet Inc. (NASDAQ: FTNT) was upgraded at Merrill Lynch to Buy. Shares closed at $79.02, in a 52-week range of $64.41 to $96.96. The consensus price target is $91.35.
FMC Corp. (NYSE: FMC) was upgraded to a Buy rating at Goldman Sachs. Shares closed at $85.06, in a 52-week range of $60.16 to $87.99. The consensus price target is $97.45.
Iron Mountain Inc. (NYSE: IRM) was upgraded to Neutral with a $29 price target by Baird. Shares closed at $30.83. The 52-week range is $28.62 to $35.97, and the consensus price target is $35.00.
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.